IRLAB completes recruitment for its Phase II study with IRL790 in Parkinson’s disease patients with dyskinesia
IRLAB announced today that the patient recruitment for the Phase II study with drug candidate IRL790 in Parkinson’s disease patients with dyskinesia has been concluded. The study recruitment target of 74 randomized patients has been achieved with the last patient now having entered the study and begun treatment. Following the last patient’s five-week study participation, the study data will be analyzed, and top-line results are thus expected within 10 weeks from this announcement.The clinical Phase II study (IRL790C003) is randomized, double-blind and placebo-controlled and is conducted at